Harvard Bioscience (HBIO) Cash & Equivalents (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cash & Equivalents data on file, last reported at $7.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 27.98% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 27.98% increase from a year earlier, with the FY2025 full-year figure at $8.6 million, up 109.69% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $7.1 million, down from $8.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for HBIO reached as high as $8.6 million in Q4 2025 and fell as low as $3.8 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $5.3 million across 5 years, with a median of $4.6 million in 2024.
• Across the five-year window, Cash & Equivalents slumped 42.36% in 2022 and surged 109.69% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $4.5 million in 2022, then dropped by 4.99% to $4.3 million in 2023, then decreased by 4.09% to $4.1 million in 2024, then jumped by 109.69% to $8.6 million in 2025, then retreated by 17.6% to $7.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.1 million in Q1 2026, $8.6 million in Q4 2025, and $6.8 million in Q3 2025.